Abstract
This article is a summary of good adaptive practices for the planning and implementation of adaptive designs compiled from experiences gained in the pharmaceutical industry. The target audience is anyone involved in the planning and execution of clinical trials. The first step prior to planning an adaptive design is to assess the appropriateness of its use. Hence, strategic points to consider when assessing if an adaptive design is the right choice for a trial are discussed. In addition, strategic points for consideration at the design and implementation stage are included from operational, regulatory, clinical, and statistical perspectives. Good practices for trial simulation, trial documentation, and data monitoring committees are provided.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gallo P, Chuang-Stein C, Dragaiin V, Gaydos B, Krams M, Pinheiro J. Executive summary of the PhRMA Working Group on Adaptive Designs in Clinical Drug Development. J Biopharm Stat. 2006;16:275–283.
PhRMA Working Group on Adaptive Designs. Full white paper. Drug Inf J. 2006;40:421–484.
Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Inf J. 2006;40:437–444.
Gaydos B, Krams M, Perevozskaya I, et al. Adaptive dose response studies. Drug Inf J. 2006; 40:451–461.
Bornkamp B, Bretz F, Dmitrienko A, et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat. 2007;17:965–995. Available at: https://doi.org/biopharmnet.com/doc/doc12005.html.
Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M. Adaptive seamless phase II/III designs—background, operational aspects, and examples. Drug Inf J. 2006;4:463–473.
Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Comm Stat. 1992;(A)21:2833–2853.
Sandvik L, Erikssen J, Mowinckel P, Rodland EA. A method for determining the size of internal pilot studies. Stat Med. 1996;15:1587–1590.
Chuang-Stein C, Anderson K, Gallo P, Collins S. Sample size reestimation: a review and recommendations. Drug Inf J. 2006;40:475–484.
Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo J-M, Ford GA. Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose response study of UK-279,276 in acute ischemic stroke. Stroke. 2003;34:2543–2548.
Berry DA, Müller P, Grieve AP, et al. Adaptive Bayesian designs for dose-ranging drug trials. In Gatsonis C, Carlin B, Carriquiry A, eds., Case Studies in Bayesian Statistics V:99–181. New York: Springer-Verlag; 2001.
Berry DA. Bayesian clinical trials. Nature Rev Drug Discovery. 2006;5:27–36.
Gallo P, Chuang-Stein C. What should be the role of homogeneity testing in adaptive trials? Pharm Stat. 2009;8:1–4.
Posch M, Koenig F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Stat Med. 2005; 24:3697–3714.
Brannath W, König F, Bauer P. Estimation in flexible two-stage designs. Stat Med. 2005;25: 3366–3381.
Brannath W, Posch M, Bauer P. Recursive combination tests. J Am Stat Assoc. 2002;97:236–244.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gaydos, B., Anderson, K.M., Berry, D. et al. Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development. Ther Innov Regul Sci 43, 539–556 (2009). https://doi.org/10.1177/009286150904300503
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150904300503